Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TAHOE: rovalpituzumab tesirine versus topotecan in DLL3-high relapsed small cell lung cancer
2016-003726-17Phase 3Completed
- Sponsor
- AbbVie Inc.
- Start
- May 2017
- Modality
- Small Molecules, Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial in small cell lung cancer (SCLC) comparing Rovalpituzumab tesirine with Topotecan (2 arms). Primary endpoint: Overall survival. Started May 2017; status: completed.
02
Drugs
rovalpituzumab tesirinetopotecan
03
Conditions
small cell lung cancer (SCLC)
Beyond the preview
Go deeper on 2016-003726-17.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2016-003726-17.